Introducing the MUC16 Gene: Implications for Prevention and Early Detection in Epithelial Ovarian Cancer

Abstract

More than 24,000 women in the United States are diagnosed with ovarian cancer every year, and half of these women die from their disease. Stage 1 ovarian cancer is curable in 95% of cases; however, due to inadequate screening tools and lack of symptoms in early disease, ovarian cancer is generally at Stage 3 or 4 when finally diagnosed. CA125 is a tumor antigen used to monitor the progression and regression of epithelial ovarian cancer. When its levels are elevated postsurgery (hysterectomy/salpingo-oophorectomy with or without peritoneal washings and lymph node biopsy) and postchemotherapy, it is suggestive of recurrent disease. Due to its similarly elevated levels in some nonmalignant conditions, however, it is not specific enough to be used for population screening. The CA125 molecule is considered a very large glycoprotein because of its molecular weight, and it has three domains: the carboxy terminal domain, the extracellular domain, and the amino terminal domain. MUC16 is the gene that encodes the peptide moiety of the CA125 molecule. MUC16 domains provide novel opportunities to develop newassays and refine current tools to improve the sensitivity and specificity of CA125 for population-based screening guidelines.

Keywords

ovarian cancer CA125 MUC16 genetics early detection

Get full access to this article

View all access options for this article.

References

Alberts, B. , Johnson, A. , Lewis, J. , Raff, M. , Roberts, K. ,& Walter, P. (2002). Molecular biology of the cell(4th ed.). New York: Garland Science.

American Cancer Society . (2004a). Cancer facts and figures 2004. Retrieved May 7, 2004, from http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf

American Cancer Society . (2004b). Cancer prevention and early detection 2004. Retrieved May 7, 2004, from http://www.cancer.org/downloads/STT/CPED2004PWSecured.pdf

Bast, R.C. , Feeney, M. , Lazarus, H. , Nadler, L. , Colvin, R.B. , & Knapp, R.C. (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. Journal of Clinical Investigation, 68,1331-1337.

Bork, P. , & Patthy, L. (1995). The SEA module: A new extracellular domain associated with O-glycosylation. Protein Science, 4, 1421-1425.

Fendrick, J. L , Konishi, I. , Geary, S. M. , Parmley, T. H. , Quirk, J. G. , & O’Brien, J. J. (1997). CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumor Biology, 18, 278-289.

He, S. , Hurwitz, D. I. , Jackson, J. D. , Jacobs, A. R. , Lanczycki C. J. , Liebert, C. A. , et al. (2003). MMDB: Entrez’s 3D-structure database. Nucleic Acids Research, 31(1), 474-477.

Legname, G. , Baskakov, I. V. , Nguyen, B. H. O. , Riesner, D. , Cohen, F. E. , DeArmond, S. J. , et al. (2004). Synthetic mammalian prions. Science, 305(5684), 673-676.

Maeda, T. , Inoue, M. , Koshiba, S. , Yabuki, T. , Aoki, M. , Nunokawa, E. , et al. (2003). Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). Journal of Biological Chemistry, 279, 13174-13182.

10.

National Cancer Institute . (2004). Ovarian cancer. Retrieved May 7, 2004, from http://www.cancer.gov/cancertopics/types/ovarian

11.

O’Brien, T. , Beard, J. B. , Underwood, L. J. , Dennis, R. A. , Santin, A. D. , & York, L. (2001). The CA125 gene: An extracellular superstructure dominated by repeat sequences. Tumor Biology, 22, 348-366.

12.

Rump, A. , Morikawa, Y. , Tanaka, M. , Minami, S. , Umesaki, N. , Takeuchi, M. , et al. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. Journal of Biological Chemistry, 279(10), 9190-9198.

13.

Tuxen, M. K. , Soletormos, G. , Rustin, G. J. S. , Nelstrop, A. E. , & Dombernowsky, P. (2000). Biological variation and analytical imprecision of CA125 in patients with ovarian cancer. Scandinavian Journal of Clinical Laboratory Investigation, 60, 713-722.

14.

Whitehouse, C. , & Solomon, E. (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecologic Oncology, 88, S152-S157.

15.

Yin, B. W. T. & Lloyd, K. O. (2001). Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. The Journal of Biological Chemistry, 276(29), 27371-27375.